Although single agent dasatinib has minimal activity in ovarian cancer clinical trial [58], a current trial assessing clinical activity of dasatinib includes OCCC patients and their ARID1A expression status (NCT02059265). The gene discussed is ARID1A; the disease is ovarian carcinoma.